Dual Tumor Exosome Biomarker Co-recognitions Based Nanoliquid Biopsy for the Accurate Early Diagnosis of Pancreatic Cancer

Pancreatic cancer, with extremely limited treatment optionsandpoor prognosis, urgently needs a breakthrough in early diagnosis andmonitoring. Tumor exosomes (T-Exos) detection is presently one ofthe most clinically significant liquid biopsy approaches for non-invasivepancreatic cancer early diagnosis, which, unfortunately, cannot beapplied as a routine diagnostic tool until a number of obstacles,such as unsatisfactory specificity and sensitivity, as well as labor-intensivepurification and analysis procedures by ultracentrifugation and enzyme-linkedimmunosorbent assay, are overcome. Here, we report a facile nanoliquidbiopsy assay for the especially specific, ultrasensitive yet economicalT-Exos detection by a dual specific biomarker antigen co-recognitionand capturing strategy, which is enabled by grafting two correspondingcapture antibodies on magnetic nanoparticles and gold nanoparticles,for the accurate detection of target tumor exosomes. This approachexhibits excellent specificity and ultrahigh sensitivity of detectingas low as 78 pg/mL pancreatic cancer exosome specific protein GPC1.Successful screening of 21 pancreatic cancer samples from 22 normalcontrol cases with the enhanced specificity and sensitivity ensuresthe promising non-invasive monitoring and diagnosis for early stagepancreatic cancer.